Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities

por Gruber-Filbin, Mariella, Dabral, Sukriti K., Pazyra-Murphy, Maria F., Ramkissoon, Shakti, Kung, Andrew L., Pak, Ekaterina, Chung, Jarom, Theisen, Matthew A., Sun, Yanping, Franchetti, Yoko, Sun, Yu, Shulman, David S., Redjal, Navid, Tabak, Barbara, Beroukhim, Rameen, Wang, Qi, Zhao, Jean, Dorsch, Marion, Buonamici, Silvia, Ligon, Keith L., Kelleher, Joseph F., Segal, Rosalind A.
Publicado em 2013

LGG-44. A PHASE I DOSE ESCALATION TRIAL OF THE MEK1/2 INHIBITOR MEK162 (BINIMETINIB) IN CHILDREN WITH LOW-GRADE GLIOMAS AND OTHER RAS/RAF PATHWAY-ACTIVATED TUMORS

por Robison, Nathan, Pauly, Jasmine, Malvar, Jemily, Gruber-Filbin, Mariella, de Mola, Rebecca Loret, Dorris, Kathleen, Bendel, Anne, Bowers, Daniel, Bornhorst, Miriam, Gauvain, Karen, Leary, Sarah, Diaz, Patricia, Tan, Yi Juin, Margol, Ashley, Dhall, Girish, Rosser, Tena, Bandopadhayay, Pratiti, Davidson, Tom, Ullrich, Nicole, Borchert, Mark, Nelson, Marvin, Sinai, Claire, Ligon, Keith, Sposto, Richard, Kieran, Mark
Publicado no Neuro Oncol (2018)